This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2013 Dec 19;504(7480):S1.

doi: 10.1038/504S1a.

Cancer immunotherapy

PMID: 24352357
DOI: 10.1038/504S1a

Cancer immunotherapy

Lauren Gravitz. Nature. 2013.

. 2013 Dec 19;504(7480):S1.

doi: 10.1038/504S1a.

Author

PMID: 24352357
DOI: 10.1038/504S1a

No abstract available

PubMed Disclaimer

Comment in

Immunotherapy: Natural killers take on cancer.
Zimmer J. Zimmer J. Nature. 2014 Jan 23;505(7484):483. doi: 10.1038/505483e. Nature. 2014. PMID: 24451532 No abstract available.

Similar articles

A new hotspot for cancer immunotherapy?
Lewis JJ, Janetzki S. Lewis JJ, et al. Cancer J Sci Am. 1998 Sep-Oct;4(5):298-9. Cancer J Sci Am. 1998. PMID: 9815292 No abstract available.
Introduction to The Renaissance of Cancer Immunotherapy.
Finn OJ, Schuler G. Finn OJ, et al. Ann N Y Acad Sci. 2013 May;1284:v-vii. doi: 10.1111/nyas.12153. Ann N Y Acad Sci. 2013. PMID: 23651200 No abstract available.
Cancer immunotherapy shows promise in multiple tumor types.
Heger M. Heger M. Nat Med. 2012 Jul 6;18(7):993. doi: 10.1038/nm0712-993. Nat Med. 2012. PMID: 22772534 No abstract available.
Overview: immunotherapy for cancer--is it time for the kitchen sink?
Davis TA. Davis TA. Curr Opin Investig Drugs. 2002 Jan;3(1):130-1. Curr Opin Investig Drugs. 2002. PMID: 12054063 Review. No abstract available.
Cancer immunotherapy.
Baxevanis CN, Perez SA, Papamichail M. Baxevanis CN, et al. Crit Rev Clin Lab Sci. 2009;46(4):167-89. doi: 10.1080/10408360902937809. Crit Rev Clin Lab Sci. 2009. PMID: 19650714 Review.

See all similar articles

Cited by

New emerging targets in cancer immunotherapy: the role of LAG3.
Puhr HC, Ilhan-Mutlu A. Puhr HC, et al. ESMO Open. 2019 Mar 12;4(2):e000482. doi: 10.1136/esmoopen-2018-000482. eCollection 2019. ESMO Open. 2019. PMID: 31231559 Free PMC article. Review.
Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Ruffo E, et al. Semin Immunol. 2019 Apr;42:101305. doi: 10.1016/j.smim.2019.101305. Semin Immunol. 2019. PMID: 31604537 Free PMC article. Review.
Manganese molybdate nanodots with dual amplification of STING activation for "cycle" treatment of metalloimmunotherapy.
Lei H, Li Q, Li G, Wang T, Lv X, Pei Z, Gao X, Yang N, Gong F, Yang Y, Hou G, Chen M, Ji J, Liu Z, Cheng L. Lei H, et al. Bioact Mater. 2023 Aug 8;31:53-62. doi: 10.1016/j.bioactmat.2023.07.026. eCollection 2024 Jan. Bioact Mater. 2023. PMID: 37601278 Free PMC article. Review.
A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8⁺ T cell responses.
Zhai W, Zhou X, Wang H, Li W, Chen G, Sui X, Li G, Qi Y, Gao Y. Zhai W, et al. Acta Pharm Sin B. 2020 Jun;10(6):1047-1060. doi: 10.1016/j.apsb.2020.01.005. Epub 2020 Jan 13. Acta Pharm Sin B. 2020. PMID: 32642411 Free PMC article.
Recent progress of metal-based nanomaterials with anti-tumor biological effects for enhanced cancer therapy.
Lei H, Pei Z, Jiang C, Cheng L. Lei H, et al. Exploration (Beijing). 2023 Jun 30;3(5):20220001. doi: 10.1002/EXP.20220001. eCollection 2023 Oct. Exploration (Beijing). 2023. PMID: 37933288 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- Ovid Technologies, Inc.
Other Literature Sources
- scite Smart Citations